JW LIFESCIENCE CORPORATION (234080) Stock Price & Analysis

234080 Stock Chart & Stats

$10,510.00-$80.00(-0.76%)

At close: Oct 30 3:30 PM GMT+9

Day’s Range: $10,450.00 - $10,650.00
52-Week Range: $10,330.00 - $15,580.00
Previous Close: $10,590.00
Volume: N/A
Average Volume (3M): 13.46K
Market Cap: KRW 162.74B
Enterprise Value: KRW 199.73B
Total Cash (Recent Filing): KRW 9.00B
Total Debt (Recent Filing): KRW 32.37B
Price to Earnings (P/E): 6.3
Beta: 0.07
Next Earnings: Nov 16, 2026 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: Mar 31, 2026
Dividend Yield: 5.23%

Bulls Say, Bears Say

Bulls Say

Resilient Revenue Growth

Revenue expanded steadily from 2022–2025 and TTM revenue remained above the prior year, indicating resilient demand. This trajectory supports the company’s operating base over the next several quarters, even as growth moderates, and provides scope to sustain investment in its pharmaceuticals business.

Conservative Balance Sheet

Debt relative to equity has declined meaningfully from 2022 to TTM while equity increased, giving JW Lifescience a stronger capital base. Conservative leverage should preserve financing flexibility and reduce balance-sheet strain as the company manages slower growth and normalizing profitability.

Positive Free Cash Flow

Cash generation is generally positive, with consistent free cash flow and a strong TTM rebound after the 2025 dip. This supports internally funded operations and capital needs, although the benefit is tempered by volatility and conversion below net income in the latest period.

Bears Say

Weaker Earnings Momentum

EPS growth of -47.4% and the financial review’s reference to earnings normalization show that recent profit momentum has weakened materially. Even with revenue resilience, lower earnings power can limit reinvestment, dividend-growth capacity, and returns on equity over the next few quarters.

Margin Compression

TTM net margin of about 10% and EBIT margin of about 13% remain solid, but both are below the unusually strong 2024 levels. This normalization indicates that prior profitability may not be fully sustainable, leaving earnings more sensitive to pricing, mix, or cost pressure.

Uneven Cash Conversion

Cash conversion is uneven: in the latest period operating and free cash flow were each only about three-quarters of net income, and 2025 had weaker coverage with negative FCF growth. If persistent, this gap could reduce flexibility to fund growth and shareholder distributions from internally generated cash.

234080 FAQ

What was JW LIFESCIENCE CORPORATION’s price range in the past 12 months?

JW LIFESCIENCE CORPORATION lowest stock price was $10330.00 and its highest was $15580.00 in the past 12 months.

What is JW LIFESCIENCE CORPORATION’s market cap?

JW LIFESCIENCE CORPORATION’s market cap is ₩162.74B.

When is JW LIFESCIENCE CORPORATION’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were JW LIFESCIENCE CORPORATION’s earnings last quarter?

JW LIFESCIENCE CORPORATION released its earnings results on Aug 14, 2026. The company reported $517.562 earnings per share for the quarter.

Is JW LIFESCIENCE CORPORATION overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does JW LIFESCIENCE CORPORATION pay dividends?

JW LIFESCIENCE CORPORATION pays a ― dividend of $550 which represents an annual dividend yield of 5.23%. See more information on JW LIFESCIENCE CORPORATION dividends here

What is JW LIFESCIENCE CORPORATION’s EPS estimate?

JW LIFESCIENCE CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does JW LIFESCIENCE CORPORATION have?

JW LIFESCIENCE CORPORATION has 15,834,554 shares outstanding.

What happened to JW LIFESCIENCE CORPORATION’s price movement after its last earnings report?

JW LIFESCIENCE CORPORATION reported an EPS of $517.562 in its last earnings report. Following the earnings report the stock price went up 1.136%.

Which hedge fund is a major shareholder of JW LIFESCIENCE CORPORATION?

Currently, no hedge funds are holding shares in KR:234080

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description